Avinger (NASDAQ:AVGR) and Cardiovascular Systems (NASDAQ:CSII) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, analyst recommendations, profitability, earnings, risk, institutional ownership and valuation.
Risk and Volatility
Avinger has a beta of 0.86, suggesting that its stock price is 14% less volatile than the S&P 500. Comparatively, Cardiovascular Systems has a beta of 2.49, suggesting that its stock price is 149% more volatile than the S&P 500.
Earnings & Valuation
This table compares Avinger and Cardiovascular Systems’ gross revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Avinger||$9.93 million||1.51||-$48.73 million||($70.07)||-0.02|
|Cardiovascular Systems||$217.04 million||5.90||$1.71 million||$0.05||764.00|
Cardiovascular Systems has higher revenue and earnings than Avinger. Avinger is trading at a lower price-to-earnings ratio than Cardiovascular Systems, indicating that it is currently the more affordable of the two stocks.
This table compares Avinger and Cardiovascular Systems’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Institutional and Insider Ownership
1.5% of Avinger shares are held by institutional investors. Comparatively, 84.6% of Cardiovascular Systems shares are held by institutional investors. 1.5% of Avinger shares are held by company insiders. Comparatively, 3.3% of Cardiovascular Systems shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
This is a summary of recent ratings and target prices for Avinger and Cardiovascular Systems, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Cardiovascular Systems has a consensus price target of $37.00, suggesting a potential downside of 3.14%. Given Cardiovascular Systems’ higher possible upside, analysts clearly believe Cardiovascular Systems is more favorable than Avinger.
Cardiovascular Systems beats Avinger on 13 of the 14 factors compared between the two stocks.
Avinger, Inc., a commercial-stage medical device company, designs, manufactures, and sells image-guided and catheter-based systems used by physicians to treat patients with peripheral arterial disease (PAD) in the United States and Europe. It develops lumivascular platform that integrates optical coherence tomography visualization with interventional catheters to provide real-time intravascular imaging during the treatment portion of PAD procedures. The company’s lumivascular products comprise Lightbox imaging consoles, as well as the Ocelot family of catheters, which are designed to penetrate a total blockage in an artery; and Pantheris, an image-guided atherectomy device that allows physicians to precisely remove arterial plaque in PAD patients. In addition, its first-generation chronic total occlusion (CTO)-crossing catheters, Wildcat, and Kittycat 2, which employs a proprietary design that uses a rotational spinning technique allowing the physician to switch between passive and active modes when navigating across a CTO. The company sells and markets its products to interventional cardiologists, vascular surgeons, and interventional radiologists. Avinger, Inc. was founded in 2007 and is headquartered in Redwood City, California.
About Cardiovascular Systems
Cardiovascular Systems, Inc., a medical device company, develops, manufactures, and commercializes various devices to treat vascular and coronary diseases in the United States. The company offers peripheral arterial disease products, including Diamondback 360 Peripheral, Predator 360, Stealth 360 Peripheral Orbital Atherectomy System (OAS), Diamondback 360 60cm Peripheral OAS, Diamondback 360 Low Profile Peripheral, Diamondback 360 1.50 Peripheral, Diamondback 360 2.00 Peripheral, Diamondback 360 200cm Peripheral, and Diamondback 360 180cm Peripheral, which are catheter-based platforms for treating a range of plaque types in leg arteries above and below the knee, including calcified plaque, as well as address various limitations associated with surgical, catheter, and pharmacological treatment alternatives. It also provides Diamondback 360 Coronary OAS, an atherectomy device for the treatment of calcified coronary arteries. Cardiovascular Systems, Inc. was founded in 1989 and is headquartered in St. Paul, Minnesota.
Receive News & Ratings for Avinger Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Avinger and related companies with MarketBeat.com’s FREE daily email newsletter.
This post was originally published on *this site*